SETBP1 and neoplasm: Furthermore, specific variants of STYMIE, such as STYMIE #30, demonstrated prominent tumor inhibition compared to STYMIE #1, emphasizing the critical role of engineered SEB variants in enhancing immune cell activation for combating tumors.